163706-06-7 Usage
Uses
Different sources of media describe the Uses of 163706-06-7 differently. You can refer to the following data:
1. Anti-platelet agent.
2. Cangrelor is a P2Y12 inhibitor used as an antiplatelet drug for intravenous application.
Definition
ChEBI: A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions
N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.
Clinical Use
Direct P2Y12 platelet receptor antagonist:
Antiplatelet for patients undergoing a PCI
Drug interactions
Potentially hazardous interactions with other drugs
None known
Metabolism
Cangrelor is deactivated rapidly in the plasma by
dephosphorylation to form its main metabolite, a
nucleoside. Following a 2 micrograms/kg/min infusion of
[3
H] cangrelor, 58% was found in urine and the remaining
35% was found in faeces, presumably following biliary
excretion.
Check Digit Verification of cas no
The CAS Registry Mumber 163706-06-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,3,7,0 and 6 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 163706-06:
(8*1)+(7*6)+(6*3)+(5*7)+(4*0)+(3*6)+(2*0)+(1*6)=127
127 % 10 = 7
So 163706-06-7 is a valid CAS Registry Number.
163706-06-7Relevant articles and documents
Antagonists of the platelet P(2t) receptor: A novel approach to antithrombotic therapy
Ingall, Anthony H.,Dixon, John,Bailey, Andrew,Coombs, Mandy E.,Cox, David,McInally, Judith I.,Hunt, Simon F.,Kindon, Nicholas D.,Teobald, Barry J.,Willis, Paul A.,Humphries, Robert G.,Leff, Paul,Clegg, Jane A.,Smith, James A.,Tomlinson, Wendy
, p. 213 - 220 (2007/10/03)
The platelet P(2T) receptor plays a major role in platelet aggregation, and its antagonists are predicted to have significant therapeutic potential as antithrombotic agents. We have explored analogues of adenosine triphosphate (ATP), which is a weak, nonselective but competitive P(2T), receptor antagonist. Modification of the polyphosphate side chain to prevent breakdown to the agonist adenosine diphosphate (ADP) and substitution of the adenine moiety to enhance affinity and selectivity for the P(2T) receptor led to the identification of 10e (AR-C67085MX), having an IC50 of 2.5 nM against ADP-induced aggregation of human platelets. Compound 10e was the first very potent antagonist of the P(2T) receptor, with a selectivity for that subtype of the P2 receptor family of > 1000-fold. Further modification of the structure produced compound 101 (AR-C69931MX) having an IC50 of 0.4 nM. In vivo, at maximally effective antithrombotic doses, there is little prolongation of bleeding time (1.4-fold), which is in marked contrast to the 5-6 fold found with GPIIb/IIIa antagonists.
